CLINICAL TRIALS OF BIOLOGICAL RESPONSE MODIFIERS-TASK A

这个项目是一个涉及辐射的跨学科研究工作 生物学、放射物理学、放射肿瘤学、医学肿瘤学，以及 与新靶向临床评价相关的免疫学 分子，包括基因工程抗体，抗体 片段和融合蛋白，用于选择性递送放射性 同位素毒素或免疫攻击机制 初始临床 目前正在进行的方案包括使用腹膜内177 Lu- 标记的CC 49通过腹膜内输注， 大量的紫杉醇（放射增敏剂），在治疗复发性卵巢癌 癌症（中等肿瘤负荷）。 其他临床方案包括 检查全身照射加I31 I放射性标记的 抗体利用自体干细胞支持探索骨髓 前列腺癌和乳腺癌的消融剂量方案。 这个程序 不久将开始研究EGF的单克隆抗体 受体，结合外部光束辐射治疗 头颈部癌症 这些研究包括毒性、临床 功效， 药代动力学、免疫原性和组织定位 成分，以科学地评估功效或 这些策略的缺点。 我们将进一步评估 其他 纳入未来I期和II期的新靶向药物 临床试验

This project is an interdisciplinary research effort involving radiation biology, radiation physics, radiation oncology, medical oncology, and immunology relating to the clinical evaluation of new targeting molecules, including genetically engineered antibodies, antibody fragments and fusion proteins, for the selective delivery of radioactive isotopes, toxins or immunologic attack mechanisms. Initial clinical protocols currently underway include the use of intraperitoneal 177Lu- labeled CC49 by intraperitoneal infusion, in the presence of varying amounts of taxol (radiosensitizer), in the treatment of recurrent ovarian cancer (modest tumor burden). Additional clinical protocols are examining the use of total body irradiation plus I31I-radiolabeled antibodies utilizing autologous stem cell support to explore marrow ablative dosage regimens in prostate and breast carcinoma. This program will shortly initiate studies to examine monoclonal antibodies to EGF receptor, in combination with external beam radiation for the treatment of head and neck cancer. These studies include both toxicity, clinical efficacy, pharmacokinetics, immunogenicity, and tissue localization components, in order to scientifically evaluate the efficacy or shortcomings of these strategies. We will be further evaluating other new targeting agents for inclusion into future phase I and phase II clinical trials.